Graph takes few seconds to load...
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
| Annual Data | Millions of US $ except per share data |
|---|
| Cash on hand |
| Receivables |
| Inventory |
| Pre-Paid Expenses |
| Other Current Assets |
| Total Current Assets |
| Property, Plant, And Equipment |
| Long-Term Investments |
| Goodwill And Intangible Assets |
| Other Long-Term Assets |
| Total Long-Term Assets |
| Total Assets |
| Total Current Liabilities |
| Long Term Debt |
| Other Non-Current Liabilities |
| Total Long Term Liabilities |
| Total Liabilities |
| Common Stock Net |
| Retained Earnings (Accumulated Deficit) |
| Comprehensive Income |
| Other Share Holders Equity |
| Share Holder Equity |
| Total Liabilities And Share Holders Equity |
